Zimmer Biomet Boosts FY25 Outlook

Medical technology firm Zimmer Biomet Holdings Inc. (ZBH) raised its full-year 2025 guidance after reporting second-quarter results, now forecasting adjusted earnings of $8.10-$8.30 per share, an increase from its prior $7.90-$8.10 range. The company also improved its reported revenue growth outlook to 6.7-7.7% and provided organic constant currency revenue growth guidance of 3.5-4.5%, signaling a strengthened financial outlook for the coming fiscal year.

Analysis

Zimmer Biomet Holdings Inc. (ZBH) has issued a significant upward revision to its full-year 2025 financial guidance, signaling strong underlying business momentum. The company raised its adjusted earnings per share forecast to a range of $8.10-$8.30, a notable increase from the prior $7.90-$8.10 range. The new midpoint of $8.20 now sits comfortably above the analyst consensus estimate of $7.99 per share. Concurrently, ZBH has tightened and raised its revenue growth forecast, now projecting reported growth of 6.7% to 7.7%, which compares favorably to the consensus estimate of 6.48%. This revision reflects greater management confidence, as the floor of the guidance range was lifted substantially from the previous 5.7%. The introduction of a specific organic constant currency revenue growth forecast of 3.5% to 4.5% provides further clarity on the core operational performance, stripping out currency and M&A effects, and reinforces the positive outlook.

Key Decisions for Investors

• Investors should note that the revised full-year 2025 guidance for both adjusted EPS and revenue growth now surpasses consensus analyst estimates, signaling a strong likelihood of positive earnings revisions and potential upward momentum for the stock.
• The tightening of the revenue growth forecast range, particularly the raised floor, indicates increased management confidence and potentially reduced execution risk, which could warrant a re-evaluation of ZBH's valuation multiples.
• It is prudent to monitor the newly introduced organic constant currency revenue growth metric of 3.5% to 4.5%, as this will be a key performance indicator for the underlying health of the business, independent of currency fluctuations or acquisition impacts.